Save the Date for ACT-AD’s Tenth Annual FDA/AD Allies Meeting, November 16
Mark your calendars! ACT-AD’s Tenth Annual FDA/AD Allies Meeting is set for Thursday, November 16, 2017, at the Bethesda North Marriott Hotel and Conference Center (5701 Marinelli Road, North Bethesda, Maryland 20852). The meeting will begin at 9:30 a.m. and end by 4:00 p.m. To register for the event, go here.
Check Out This Webinar on Alzheimer’s Disease Research Framework
On July 25, ACT-AD hosted a webinar on the updated National Institute on Aging-Alzheimer’s Association Research Framework for Alzheimer’s Disease. The one-hour program featured expert perspectives on the topic. Clifford R. Jack Jr. M.D., of the Mayo Clinic, and Paul Stephen Aisen, M.D., of USC, were the featured speakers. The archived webinar can be viewed here.
Researchers Say Vascular Health Could Impact Risk of Dementia
The National Institutes of Health (NIH) funded a long-term study that found middle-aged Americans with vascular health risk factors may have a greater chance of developing dementia. “Our results contribute to a growing body of evidence linking midlife vascular health to dementia,” said Dr. Rebecca Gottesman, professor of neurology at Johns Hopkins University. “These are modifiable risk factors. Our hope is that by addressing these types of factors early, people can reduce the chances that they will suffer from dementia later in life.” To learn more, go here.
Transport of Lysosomes Could Play Role in Progression of Alzheimer’s Disease
A team of researchers at the Yale University School of Medicine found that defects in the transport of lysosomes within the brain’s neurons advance the buildup of proteins in animal models. The findings could assist in improved lysosome transport, which could lead to advanced therapeutic approaches to treat Alzheimer’s disease. To read the full study in The Journal of Cell Biology, go here.
New Method May Determine Dementia Diagnoses
Researchers discovered that a noninvasive technique called transcranial magnetic stimulation (TMS) could assist in determining whether a person has Alzheimer’s disease or frontotemporal dementia. The two types of dementia often have similar symptoms and this finding could help physicians make correct diagnoses. “Doctors might soon be able to quickly and easily diagnose frontotemporal dementia with this non-invasive procedure. This disease unfortunately can’t be cured, but it can be managed — especially if it is caught early,” said study author Barbara Borroni, M.D., of the University of Brescia in Italy. To learn more, go here.
Research Study Evaluates Investigational Medication That Targets Tau Protein
The Aware Study is evaluating an investigational medication targeting the tau protein to see if it may slow the progression of Early Alzheimer’s disease. People with Alzheimer’s disease have more abnormal tau protein in their brains. Some doctors and scientists think the build-up of tau protein may worsen Alzheimer’s symptoms. It may be important to identify symptoms early. To learn more about the Aware Study visit, www.AlzheimersAwareStudy.com or call 844-92-AWARE (844-922-9273).
Science Advisory Board Member George Perry Creates Online Course on Alzheimer’s Disease
Science Advisory Board Member George Perry, Ph.D., developed an online course at The University of Texas at San Antonio that emphasizes the progression of Alzheimer’s disease from molecular and genetic perspectives. The free course will give students the opportunity to “explore the history of Alzheimer’s disease and identify the major scholars who contributed to the advancement of the research in addition to helping them understand the correlation between clinical disease, morphologic changes and molecular pathways.” The course launches on August 28 and enrollment is open now. Learn more here.
ADDF’s Conference on Alzheimer’s Drug Discovery, September 11-12, 2017
The Alzheimer’s Drug Discovery Foundation will hold its 18th Annual International Conference on Alzheimer’s Drug Discovery in Jersey City, New Jersey. The two-day event will gather top researchers, who are developing innovative treatments for Alzheimer’s disease and related dementias. General details about the conference are available here.
AFA Hosts National Educating America Tour, September 14, 2017
The Alzheimer’s Foundation of America will host their “National Educating America Tour,” as part of their Concepts in Care Educational Conferences in Washington, D.C. (1526 New Hampshire Ave., NW). The free event will allow attendees to hear from experts on a variety of topics such as access to health care, long-term care, perceptions of aging, and research. Registration details can be found here.